Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution

Ingrid Burger, Kelvin Hong, Richard Schulick, Christos Georgiades, Paul Thuluvath, Michael Choti, Ihab Kamel, Jean Francois H Geschwind

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

PURPOSE: Unresectable cholangiocarcinoma carries a dismal prognosis, with median survival times ranging from 6 to 12 months from the time of diagnosis. Palliative therapies have been disappointing and have not been shown to significantly prolong survival. Conversely, transcatheter arterial chemoembolization (TACE) has been effective in prolonging the lives of patients with hepatocellular carcinoma but has not been used against cholangiocarcinoma. Therefore, the purpose of the present study was to assess the safety and efficacy (ie, survival) of TACE in patients with unresectable intrahepatic cholangiocarcinoma. MATERIALS AND METHODS: Seventeen patients with unresectable cholangiocarcinoma were treated with one or more cycles of TACE between 1995 and 2004 at our institution. Follow-up imaging was performed on all patients 4-6 weeks after each TACE procedure to determine tumor response and need for further treatment. Survival was calculated with use of the Kaplan-Meier survival curve. RESULTS: The median survival for 17 patients treated with TACE was 23 months. Two patients with previously unresectable disease underwent successful resection after TACE. The procedure was well tolerated by 82% of the patients, who experienced no side effects or mild side effects that quickly resolved with conservative therapy alone. Two patients had minor complications (12%), which were managed successfully, and one had a major complication that resulted in a fatal outcome. This patient had a rapidly declining course from the time of diagnosis and died shortly after TACE. CONCLUSIONS: The results suggest that TACE was effective at prolonging survival of patients with unresectable cholangiocarcinoma. Therefore, for these patients, TACE may be an appropriate palliative therapy.

Original languageEnglish (US)
Pages (from-to)353-361
Number of pages9
JournalJournal of Vascular and Interventional Radiology
Volume16
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Cholangiocarcinoma
Survival
Palliative Care
Fatal Outcome
Kaplan-Meier Estimate
Hepatocellular Carcinoma
Safety

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma : Initial experience in a single institution. / Burger, Ingrid; Hong, Kelvin; Schulick, Richard; Georgiades, Christos; Thuluvath, Paul; Choti, Michael; Kamel, Ihab; Geschwind, Jean Francois H.

In: Journal of Vascular and Interventional Radiology, Vol. 16, No. 3, 03.2005, p. 353-361.

Research output: Contribution to journalArticle

Burger, Ingrid ; Hong, Kelvin ; Schulick, Richard ; Georgiades, Christos ; Thuluvath, Paul ; Choti, Michael ; Kamel, Ihab ; Geschwind, Jean Francois H. / Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma : Initial experience in a single institution. In: Journal of Vascular and Interventional Radiology. 2005 ; Vol. 16, No. 3. pp. 353-361.
@article{c16fa9fe4ea34cccbae8a0415fc644e6,
title = "Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution",
abstract = "PURPOSE: Unresectable cholangiocarcinoma carries a dismal prognosis, with median survival times ranging from 6 to 12 months from the time of diagnosis. Palliative therapies have been disappointing and have not been shown to significantly prolong survival. Conversely, transcatheter arterial chemoembolization (TACE) has been effective in prolonging the lives of patients with hepatocellular carcinoma but has not been used against cholangiocarcinoma. Therefore, the purpose of the present study was to assess the safety and efficacy (ie, survival) of TACE in patients with unresectable intrahepatic cholangiocarcinoma. MATERIALS AND METHODS: Seventeen patients with unresectable cholangiocarcinoma were treated with one or more cycles of TACE between 1995 and 2004 at our institution. Follow-up imaging was performed on all patients 4-6 weeks after each TACE procedure to determine tumor response and need for further treatment. Survival was calculated with use of the Kaplan-Meier survival curve. RESULTS: The median survival for 17 patients treated with TACE was 23 months. Two patients with previously unresectable disease underwent successful resection after TACE. The procedure was well tolerated by 82{\%} of the patients, who experienced no side effects or mild side effects that quickly resolved with conservative therapy alone. Two patients had minor complications (12{\%}), which were managed successfully, and one had a major complication that resulted in a fatal outcome. This patient had a rapidly declining course from the time of diagnosis and died shortly after TACE. CONCLUSIONS: The results suggest that TACE was effective at prolonging survival of patients with unresectable cholangiocarcinoma. Therefore, for these patients, TACE may be an appropriate palliative therapy.",
author = "Ingrid Burger and Kelvin Hong and Richard Schulick and Christos Georgiades and Paul Thuluvath and Michael Choti and Ihab Kamel and Geschwind, {Jean Francois H}",
year = "2005",
month = "3",
doi = "10.1097/01.RVI.0000143768.60751.78",
language = "English (US)",
volume = "16",
pages = "353--361",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma

T2 - Initial experience in a single institution

AU - Burger, Ingrid

AU - Hong, Kelvin

AU - Schulick, Richard

AU - Georgiades, Christos

AU - Thuluvath, Paul

AU - Choti, Michael

AU - Kamel, Ihab

AU - Geschwind, Jean Francois H

PY - 2005/3

Y1 - 2005/3

N2 - PURPOSE: Unresectable cholangiocarcinoma carries a dismal prognosis, with median survival times ranging from 6 to 12 months from the time of diagnosis. Palliative therapies have been disappointing and have not been shown to significantly prolong survival. Conversely, transcatheter arterial chemoembolization (TACE) has been effective in prolonging the lives of patients with hepatocellular carcinoma but has not been used against cholangiocarcinoma. Therefore, the purpose of the present study was to assess the safety and efficacy (ie, survival) of TACE in patients with unresectable intrahepatic cholangiocarcinoma. MATERIALS AND METHODS: Seventeen patients with unresectable cholangiocarcinoma were treated with one or more cycles of TACE between 1995 and 2004 at our institution. Follow-up imaging was performed on all patients 4-6 weeks after each TACE procedure to determine tumor response and need for further treatment. Survival was calculated with use of the Kaplan-Meier survival curve. RESULTS: The median survival for 17 patients treated with TACE was 23 months. Two patients with previously unresectable disease underwent successful resection after TACE. The procedure was well tolerated by 82% of the patients, who experienced no side effects or mild side effects that quickly resolved with conservative therapy alone. Two patients had minor complications (12%), which were managed successfully, and one had a major complication that resulted in a fatal outcome. This patient had a rapidly declining course from the time of diagnosis and died shortly after TACE. CONCLUSIONS: The results suggest that TACE was effective at prolonging survival of patients with unresectable cholangiocarcinoma. Therefore, for these patients, TACE may be an appropriate palliative therapy.

AB - PURPOSE: Unresectable cholangiocarcinoma carries a dismal prognosis, with median survival times ranging from 6 to 12 months from the time of diagnosis. Palliative therapies have been disappointing and have not been shown to significantly prolong survival. Conversely, transcatheter arterial chemoembolization (TACE) has been effective in prolonging the lives of patients with hepatocellular carcinoma but has not been used against cholangiocarcinoma. Therefore, the purpose of the present study was to assess the safety and efficacy (ie, survival) of TACE in patients with unresectable intrahepatic cholangiocarcinoma. MATERIALS AND METHODS: Seventeen patients with unresectable cholangiocarcinoma were treated with one or more cycles of TACE between 1995 and 2004 at our institution. Follow-up imaging was performed on all patients 4-6 weeks after each TACE procedure to determine tumor response and need for further treatment. Survival was calculated with use of the Kaplan-Meier survival curve. RESULTS: The median survival for 17 patients treated with TACE was 23 months. Two patients with previously unresectable disease underwent successful resection after TACE. The procedure was well tolerated by 82% of the patients, who experienced no side effects or mild side effects that quickly resolved with conservative therapy alone. Two patients had minor complications (12%), which were managed successfully, and one had a major complication that resulted in a fatal outcome. This patient had a rapidly declining course from the time of diagnosis and died shortly after TACE. CONCLUSIONS: The results suggest that TACE was effective at prolonging survival of patients with unresectable cholangiocarcinoma. Therefore, for these patients, TACE may be an appropriate palliative therapy.

UR - http://www.scopus.com/inward/record.url?scp=14844343570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844343570&partnerID=8YFLogxK

U2 - 10.1097/01.RVI.0000143768.60751.78

DO - 10.1097/01.RVI.0000143768.60751.78

M3 - Article

C2 - 15758131

AN - SCOPUS:14844343570

VL - 16

SP - 353

EP - 361

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 3

ER -